Madrigal Pharmaceuticals, Inc.
MDGLDrugs in Pipeline
2
Phase 3 Programs
2
Upcoming Catalysts
4
Next Catalyst
Aug 4, 2026
4wMarket Overview
Stock performance and key metrics
4 upcoming, 0 past
How MDGL's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Resmetirom | Phase 3 | NASH | - | - |
MGL-3196 | Phase 3 | Heterozygous Familial Hypercholesterolemia | - | - |
NASH
1 drug in this indication
Heterozygous Familial Hypercholesterolemia
1 drug in this indication
Non-Alcoholic Fatty Liver Disease
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Madrigal Pharmaceuticals, Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Madrigal Pharmaceuticals, Inc.'s (MDGL) pipeline across Phase 3. Its lead program is Resmetirom (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Madrigal Pharmaceuticals, Inc.'s next FDA catalyst?→
Madrigal Pharmaceuticals, Inc.'s (MDGL) next tracked catalyst is a Earnings expected August 4, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track MDGL biotech catalysts?→
Add MDGL to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Madrigal Pharmaceuticals, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.